Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Recruiting now · Phase 1/Phase 2

Conditions studied: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

In brief

The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in participants with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The study will begin with a safety lead-in phase (Phase 1b study) to determine the recommended combination dose (RDC) and then will transition to an expansion phase (Phase 2 study) to assess the clinical activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin at the RCD. During the treatment period participants will have study visits on days 1, 8, and 15 of Cycle 1, on days 1 and 8 of Cycle 2 to 8, and on day 1 of each additional cycle. Cycles 1 through 8 are 21 day cycles, and each following cycle is 28 days. Approximately 30 days and 90 days after treatment has ended, safety follow-up visits will occur and then participants will be followed for survival every 3 months. Study visits may include blood tests, ECG, vital signs, and a physical examination.

Key facts

Study ID: NCT06501625
Run by: Institut de Recherches Internationales Servier
People needed: 52
Starts: 2024-12-16
Expected to finish: 2027-09-13
Last updated by the study team: 2026-05-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have a histopathological confirmed diagnosis consistent with locally advanced unresectable or metastatic cholangiocarcinoma.
Have documented IDH1 gene-mutated cholangiocarcinoma based on local or central laboratory testing (R132C/L/G/H/S mutation variants tested).
Have at least one evaluable and measurable lesion as defined by RECIST v1.1.
Have adequate bone marrow function as evidenced by:
Absolute neutrophil count ≥ 1,500/mm3 or 1.5 ×109/L
Hemoglobin ≥ 9 g/dL
Platelet count ≥ 100,000/mm3 or 100 × 109/L
Have adequate hepatic function as evidenced by:
Serum bilirubin ≤ 2.0 × the upper limit of normal (ULN); this will not apply to patients with confirmed Gilbert's syndrome. Any clinically significant biliary obstruction should be resolved before randomization
Aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤ 5.0 × ULN
Have adequate renal function, defined as: creatinine clearance > 60 mL/min per 24 hour urine or as calculated on the Cockcroft-Gault formula (using actual body weight):
Creatine CL (mL/min)= (140 - Age) × (weight in kg) × (0.85 if female)/72 × serum creatinine (mg/dL)

You may not qualify if…

Received treatment for locally advanced, unresectable or metastatic disease with the following exceptions:
Treatment with up to one cycle of durvalumab plus gemcitabine/cisplatin treatment is permitted before study participation. Note: For the Safety Lead-In Phase, participants who received one prior cycle of durvalumab plus gemcitabine/cisplatin and required dose modifications for treatment-related toxicity are excluded.
Patients who developed recurrent disease > 6 months after surgery with curative intent, and, if given, > 6 months after the completion of adjuvant (chemotherapy and/or radiation).
Prior exposure to immune-mediated therapy, including, but not limited to, anti-PD-1or other anti-PD-L1, and anti-PD-L2, anti-CTLA-4 antibodies, excluding therapeutic anticancer vaccines.
Unresolved Grade ≥2 adverse events from a previous anticancer therapy, with the exception of alopecia and vitiligo and the laboratory values listed in the inclusion criteria.
Patients with Grade ≥2 neuropathy to be evaluated on a case-by-case basis after consultation with the medical monitor
Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with ivosidenib may be included only after consultation with the medical monitor
Participation in another interventional study at the same time or within 14 days prior to the first study medication (triple combination treatment) administration. For patients having participated to another prior interventional study, the first dose of ivosidenib should occur after a period greater than or equal to 5 half-lives or 28 days, whichever is shorter of the last dose of the prior investigational product.
Active or prior documented autoimmune or inflammatory disorders including:
inflammatory bowel disease (e.g., colitis or Crohn's disease)
diverticulitis (with the exception of diverticulosis)
systemic lupus erythematosus
Sarcoidosis syndrome
Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.)
Note: in cases with no active disease for ≥ 5 years, patients may be considered for inclusion if approved by the Medical Monitor. Participants with the following conditions are eligible for the study:
chronic skin condition that does not require systemic therapy
vitiligo
alopecia
hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy
unmedicated celiac disease that is controlled by diet
Have heart rate-corrected QT interval using Fridericia's formula (QTcF) of ≥ 450 msec or with other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome/sudden death, polymorphic ventricular arrhythmia). The Sponsor should review participants with bundle branch block and prolonged QTcF for potential inclusion.
Have an active infection, including:
Hepatitis B (clinical evaluation includes: presence of hepatitis B surface antigen [HBsAg] and/or anti-HBcAb with detectable hepatitis B virus [HBV] DNA ≥ 10 IU/mL)
Hepatitis C
Tuberculosis (clinical evaluation includes: clinical history, physical examination and/or radiographic findings, and tuberculosis testing as per local practice)

Where it is running

Cancer and Blood Speciality Clinic - Los Alamitos — Los Alamitos, California, United States (enrolling)
Usc Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
Northwestern Medicine — Chicago, Illinois, United States (enrolling)
Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
Duke University — Durham, North Carolina, United States (enrolling)
Gibbs Cancer Center — Spartanburg, South Carolina, United States (enrolling)
Tennesse Oncology - Elliston Place Plaza — Nashville, Tennessee, United States (enrolling)
The University of Texas Md Anderson Cancer Center — Houston, Texas, United States (enrolling)
Alfred Health — Melbourne, Australia (enrolling)
Hospital de Amor - Barretos — Barretos, Brazil (enrolling)
Oncoclinicas Mg — Belo Horizonte, Brazil (enrolling)
CIONC — Curitiba, Brazil (enrolling)
Instituto Dor de Pesquisa E Ensino Sp — São Paulo, Brazil (enrolling)
Princess Margaret Cancer Centre — Toronto, Canada (enrolling)
Institut Bergonie — Bordeaux, France (enrolling)
Hôpital Beaujon — Clichy, France (enrolling)
Chu Montpellier-Hopital Saint-Eloi — Montpellier, France (enrolling)
Charite Universitatsmedizin — Berlin, Germany (enrolling)
Universitätsklinikum Düsseldorf — Düsseldorf, Germany (enrolling)
Universitären Centrums Für Tumorerkrankungen (Uct) Der J.W. Goethe-Universität Frankfurt — Frankfurt, Germany (enrolling)
Medizinische Hochschule Hannover Oe 6810 — Hanover, Germany (enrolling)
Universitätsklinikum Ulm — Ulm, Germany (enrolling)
National Cancer Center Hospital East — Kashiwa, Chiba, Japan (enrolling)
National Cancer Center Hospital — Chūōku, Japan (enrolling)
Kyoto University Hospital — Kyoto, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.